ClinicalTrials.gg
RecruitingNCT05819476BOLPAPUpdated Jan 24, 2025

Boosting Open-Label Placebo Effects in Acute Induced Pain in Healthy Adults

An interventional study of OLP-injection and Scripted Evidence-based treatment rationale in Acute Pain, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Acute Pain with a site in Switzerland — 3 open to participants now, 3 under way, none of them phase 3. Acute Pain · Switzerland.

Planned enrollment
5th of 11
141 · median 62
Started
2023
with 1 other
No phase
10 of 16
1 open now
Registered
13th of 16
by date
Lead sponsor
2 of 16
University Hospital, Basel, Switzerland

Among the 16 studies in Acute Pain with a site in Switzerland, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2023, is one of 10 with no phase, and was the 13th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

3 of the 16 studies in Acute Pain with a site in Switzerland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Acute Pain with a site in Switzerland, or all of them as a file.
02

Study summary

This study is to investigate the effect of open-label placebo (OLP) application on acute pain in an experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).

In Part 1 duration of OLP analgesia will be examined, and onset and size of the effect will be reevaluated.

In Part 2 of this study outcomes between subjects receiving one OLP injection, subjects receiving one repetition of the injection on a fixed time point and subjects receiving one repetition of the injection on-demand will be evaluated

Read the detailed description

Pain is highly prevalent in hospital settings. Standard systemic treatment for acute pain consists mainly of basic analgesia. The use of these drugs is often restricted due to their contraindications. Placebo is used nowadays to describe sham treatments and "inert" substances like sugar pills and saline injections. Placebos are proven to elicit clinically significant effects in various conditions, including pain. Ethical concerns about the use of deceptive placebos have prevented their implementation in clinical practice. A possibility to address this issue would be to prescribe placebos openly, that means, without deception. This randomized crossover study evaluates the efficacy of open-label placebo (OLP) in acute pain. Subjective pain ratings and areas of hyperalgesia and allodynia will be measured in a well-established experimental pain model (intradermal electrical stimulation model evoking pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment) and analgesia elicited by OLP injections will be investigated.

In Part 1 duration of OLP analgesia will be examined, and onset and size of the effect will be reevaluated.

In Part 2 of this study outcomes between subjects receiving one OLP injection, subjects receiving one repetition of the injection on a fixed time point and subjects receiving one repetition of the injection on-demand will be evaluated (which leaves the last group a choice over when they would like to have the placebo "booster").

03

Conditions studied

  • Acute Pain

Keywords

  • Open-Label Placebo (OLP)
  • OLP analgesia
  • acute pain
  • hyperalgesia
  • allodynia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers (ASA Class I or II), aged 18 to 65 years
  • between 18 and 25kg/m2
  • Able to understand the study and the NRS
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Participation in a previous open-label placebo study; for Part 2, this includes Part 1 of this study
  • Regular intake of medications or drugs potentially interfering with pain sensation (analgesics, opioids, antihistamines, calcium and potassium channel blockers, serotonin/ noradrenaline reuptake inhibitors, )
  • Neuropathy
  • Chronic pain
  • Neuromuscular disease
  • Dermatological disease (i.e. Atopic Dermatitis)
  • Psychiatric disease
  • Pregnancy / Lactation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
141 participants (estimated)

Study arms

  • Other
    Part 1: Visit 1 (No treatment) followed by Visit 2 (OLP intervention)

    In Part 1, participants will receive one injection (administration of open-label placebo injections without any active ingredient (5 ml 0.9% saline)) at twenty minutes after start of the experiment during the intervention visit 2. Visit 1 (No treatment) will be the control of the study intervention.

    Procedure: OLP-injection · Other: Scripted Evidence-based treatment rationale · Other: Experimental model of acute pain

  • Other
    Part 1: Visit 1 (OLP intervention) followed by Visit 2 (No treatment)

    In Part 1, participants will receive one injection (administration of open-label placebo injections without any active ingredient (5 ml 0.9% saline)) at twenty minutes after start of the experiment during the intervention visit 1. Visit 2 (No treatment) will be the control of the study intervention.

    Procedure: OLP-injection · Other: Scripted Evidence-based treatment rationale · Other: Experimental model of acute pain

  • Other
    Part 2/ Group A: 1x OLP (Control)

    In Part 2, the Group A (Control) receives just one single OLP injection and no repetition.

    Procedure: OLP-injection · Other: Scripted Evidence-based treatment rationale · Other: Experimental model of acute pain

  • Other
    Part 2/ Group B: 2x OLP; booster time fixed

    In Part 2, Group B participants will receive two injections, the first at twenty minutes after start of the experiment, and the second at a time point derived from Part 1 (if data is inconclusive; at 100 minutes). For every subsequent OLP administration, patients will be reminded of the inertness of the injection and that this injection might help with regulating pain.

    Procedure: OLP-injection · Other: Scripted Evidence-based treatment rationale · Other: Experimental model of acute pain

  • Other
    Part 2/ Group C: 2x OLP; booster on- demand

    In Part 2, Group C participants will receive two injections, the first at twenty minutes after start of the experiment, and the second on demand. For every subsequent OLP administration, patients will be reminded of the inertness of the injection and that this injection might help with regulating pain.

    Procedure: OLP-injection · Other: Scripted Evidence-based treatment rationale · Other: Experimental model of acute pain

Interventions

  • ProcedureOLP-injection

    Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.

  • OtherScripted Evidence-based treatment rationale

    As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.

  • OtherExperimental model of acute pain

    Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).

06

What researchers measure

Primary outcomes

  1. Part 1: Change in Area under the Pain Curve (AUPC)

    Area under the Pain Curve (AUPC) using the numeric rating scale (NRS; 0 = no pain, 10 = worst imaginable pain) during three hours after administering an OLP

    Time frame: During three hours after administering an OLP

  2. Part 2: Change in Area under the Pain Curve (AUPC)

    Area under the Pain Curve (AUPC) using the numeric rating scale (NRS; 0 = no pain, 10 = worst imaginable pain). Comparison of the AUPCs of subjects receiving just one OLP injection with subjects additionally receiving one repetition of OLP administration at a time point derived from Part 1 and subjects getting the second OLP injection on-demand.

    Time frame: During three hours after administering an OLP

Secondary outcomes

  1. Part 1 and 2: Change in subjective pain ratings on each measurement point using the numeric rating scale (NRS)

    Change in subjective pain ratings on each measurement point using the numeric rating scale (NRS); NRS; 0 = no pain, 10 = worst imaginable pain) every five minutes after OLP administration)

    Time frame: Up to 200 minutes after electrical pain stimulation

  2. Part 1 and 2: Change in Area under the Curve (AUC) of area of hyperalgesia

    Change in Area under the Curve (AUC) of area of hyperalgesia comparing the intervention and control (no treatment) visit. Pinprick hyperalgesia will be assessed every 10 minutes after OLP administration) using a 600 millinewton (mN) von Frey filament.

    Time frame: Up to 200 minutes after electrical pain stimulation

  3. Part 1 and 2: Change in Area under the Curve (AUC) of area of allodynia

    Change in Area under the Curve (AUC) of area of allodynia comparing the intervention and control (no treatment) visit. Allodynia will be determined using a dry cotton swab every 10 minutes after OLP administration).

    Time frame: Up to 200 minutes after electrical pain stimulation

07

Study locations

1 of 1 sites recruiting
  • University Hospital of Basel (USB); Department of Anaesthesiology
    Basel, 4031, Switzerland
    Recruiting
    • Tobias Schneider, MD · Contacttobias.schneider@usb.ch · +41 61 328 65 43
    • Tobias Schneider, MD · Principal investigator
    • Jens Gaab, Prof. · Sub investigator
    • Matthijs de Leeuw · Sub investigator
    • Flavia Flepp · Sub investigator
    • Maria Oplliger · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jun 2025, 27 months after the start.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 27 months is above that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Apr 19, 2023
StartActual
Mar 23, 2023
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2025
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05819476
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
Mar 23, 2023
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Jan 24, 2025

Study contacts

Tobias Schneider, MD
Contact
tobias.schneider@usb.ch
+41 61 328 65 43
Tobias Schneider, MD
principal investigator · Department of Anaesthesiology, University Hospital of Basel (USB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion